ICJIM
Intercontinental Journal of Internal Medicine

The Intercontinental Journal of Internal Medicine aims to publish issues related to all fields of internal medicine of the highest scientific and clinical value at an international level and accepts articles on these topics.

eISSN: 2980-0846
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Review
The relationship between inflammatory parameters and disease severity in patients with active ulcerative colitis
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing and remitting mucosal inflammation with variable clinical severity. Accurate evaluation of disease activity is essential for treatment optimization, monitoring therapeutic response, and preventing long-term complications. Although endoscopic assessment remains the gold standard for determining mucosal inflammation, its invasive nature and limited practicality for repeated evaluation have increased interest in noninvasive inflammatory biomarkers. Recent evidence has demonstrated that several hematological and biochemical inflammatory parameters may reflect both clinical and endoscopic disease activity in UC. Acute phase reactants such as C-reactive protein (CRP) and serum albumin, along with inflammatory indices derived from the complete blood count-including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and aggregate index of systemic inflammation (AISI), have shown potential utility in predicting inflammatory burden and disease severity. In addition, fecal calprotectin has emerged as one of the most valuable noninvasive biomarkers because of its strong association with mucosal inflammation and endoscopic activity. The Montreal classification system also provides a standardized framework for assessing disease extent and clinical severity in UC. Growing evidence suggests that extensive colitis and severe disease activity are associated with elevated levels of inflammatory biomarkers and lower serum albumin concentrations. This review summarizes the current literature regarding the relationship between inflammatory biomarkers and disease severity in active UC and discusses the clinical utility, advantages, and limitations of these parameters in evaluating inflammatory activity and predicting endoscopic disease severity.

Keywords : Ulcerative colitis, inflammatory biomarkers, C-reactive protein, albumin, fecal calprotectin, endoscopic activity

Download Article


1. Adams SM, Close ED, Shreenath AP. Ulcerative colitis: rapid evidence review. Am Fam Physician. 2022;105(4):406-411.
2. Chan P, McNamara J, Vernon-Roberts A, et al. Systematic review: practices and programs in inflammatory bowel disease transition care. Inflamm Bowel Dis. 2025;31(5):1404-1418. doi:10.1093/ibd/izae190
3. Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA. 2023; 330(10):951-965. doi:10.1001/jama.2023.15389
4. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1-s106. doi:10.1136/gutjnl-2019-318484
5. Liu D, Saikam V, Skrada KA, Merlin D, Iyer SS. Inflammatory bowel disease biomarkers.Med Res Rev. 2022;42(5):1856-1887. doi:10.1002/med.21893
6. Elhag DA, Kumar M, Saadaoui M, et al. Inflammatory bowel disease treatments and predictive biomarkers of therapeutic response. Int J Mol Sci. 2022;23(13):6966. doi:10.3390/ijms23136966
7. Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease. Digestion. 2023;104(1):30-41. doi:10.1159/000527846
8. Peterson CT, Sharma V, Elmén L, Peterson SN. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota. Clin Exp Immunol. 2015;179(3):363-377. doi:10.1111/cei.12474
9. Rees WD, Sly LM, Steiner TS. How do immune and mesenchymal cells influence the intestinal epithelial cell compartment in inflammatory bowel disease? Let's crosstalk about it! J Leukoc Biol. 2020;108(1):309-321. doi:10.1002/JLB.3MIR0120-567R
10. Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis. J Basic Clin Physiol Pharmacol. 2018;30(1):1-10. doi:10.1515/jbcpp-2018-0036
11. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol. 2014;20(1):6-21. doi:10.3748/wjg.v20.i1.6
12. Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. The IL23-IL17 immune axis in the treatment of ulcerative colitis: successes, defeats, and ongoing challenges. Front Immunol. 2021;12:611256. doi:10.3389/fimmu.2021.611256
13. D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L. A Practical guide for faecal calprotectin measurement: myths and realities. J Crohns Colitis. 2021;15(1):152-161. doi:10.1093/ecco-jcc/jjaa093
14. Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One. 2013;8(3):e59321. doi:10.1371/journal.pone.0059321
15. Okba AM, Amin MM, Abdelmoaty AS, et al. Neutrophil/lymphocyte ratio and lymphocyte/monocyte ratio in ulcerative colitis as non-invasive biomarkers of disease activity and severity. Auto Immun Highlights. 2019;10(1):4. doi:10.1186/s13317-019-0114-8
16. Kamış F, Ünal Çetin E, Ugar M, Beyazıt Y. Evaluation of neutrophil- lymphocyte and platelet-lymphocyte ratios and mean platelet volume in patients with ulcerative colitis. J Med Palliat Care. 2020;1(2):28-33.
17. Xie Y, Zhuang T, Ping Y, et al. Elevated Systemic Immune-inflammation Index level is associated with disease activity in ulcerative colitis patients. Clin Chim Acta. 2021;517:122-126. doi:10.1016/j.cca.2021.02.016
18. Zinellu A, Collu C, Nasser M, et al. The aggregate index of systemic inflammation (AISI): a novel prognostic biomarker in idiopathic pulmonary fibrosis. J Clin Med. 2021;10(18):4134. doi:10.3390/jcm10184134
19. Xiu J, Lin X, Chen Q, et al. The aggregate index of systemic inflammation (AISI): a novel predictor for hypertension. Front Cardiovasc Med. 2023;10:1163900. doi:10.3389/fcvm.2023.1163900
20. Cao C, Li C, Li X, Sun W, Wang Y. Association of Systemic Immune-inflammation Index (SII) and aggregate index of systemic inflammation (AISI) with thyroid nodules in patients with type 2 diabetes mellitus: a retrospective study. BMC Endocr Disord. 2023;23(1):251. doi:10.1186/s12902-023-01509-w
21. Bai X, Cheng L, Wang H, et al. The aggregate index of systemic inflammation (AISI) and the risk of all-cause, cardiovascular, and cardio-cerebrovascular mortality in congestive heart failure patients: results from NHANES 1999-2018. Sci Rep. 2025;15(1):18282. doi:10.1038/s41598-025-01196-8
22. Don BR, Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial. 2004;17(6):432-437. doi:10.1111/j.0894-0959.2004.17603.x
23. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55(3):426-431. doi:10.1136/gut.2005.069476
24. Liu X, Pan LX, Pei JX, Pu T, Wen HT, Zhao Y. Role of serological biomarkers in evaluating and predicting endoscopic activity in inflammatory bowel disease. World J Gastroenterol. 2025;31(18):104206. doi:10.3748/wjg.v31.i18.104206
25. Chen YH, Wang L, Feng SY, Cai WM, Chen XF, Huang ZM. The relationship between C-reactive protein/albumin ratio and disease activity in patients with inflammatory bowel disease.Gastroenterol Res Pract. 2020;2020:3467419. doi:10.1155/2020/3467419
26. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26(3):411-419. doi:10.1111/j.1365-2036.2007.03383.x
27. Tenlik İ, Çoşkun O, Çapraz M, et al. Assessment of ulcerative colitis activity and severity using non-invasive biomarkers. J Acad Gastroenterol. 2023;22(2):59-66. doi:10.17941/agd.1348965
28. Khan N, Patel D, Shah Y, Trivedi C, Yang YX. Albumin as a prognostic marker for ulcerative colitis. World J Gastroenterol. 2017;23(45):8008-8016. doi:10.3748/wjg.v23.i45.8008
29. Zheng J, Zhang X, Zhang L, et al. Serum albumin and its trajectory are associated with therapeutic outcomes in ulcerative colitis. Clin Gastroenterol Hepatol. 2025;23(10):1808-1816. doi:10.1016/j.cgh.2024.10.036
30. Ishida N, Takahashi K, Asai Y, et al. Albumin change predicts failure in ulcerative colitis treated with adalimumab. PLoS One. 2024;19(1):e0295681. doi:10.1371/journal.pone.0295681
31. Tanaka M, Takagi T, Naito Y, et al. Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis. JGH Open. 2021;5(3):377-381. doi:10.1002/jgh3.12506
32. Li X, Tang Z, Liu Y, Zhu X, Liu F. Risk prediction model based on blood biomarkers for predicting moderate to severe endoscopic activity in patients with ulcerative colitis. Front Med (Lausanne). 2023;10:1101237. doi:10.3389/fmed.2023.1101237
33. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140(6):1817-1826.e2. doi:10.1053/j.gastro.2010.11.058
34. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.Gut. 2006;55(6):749-753. doi:10.1136/gut.2005.082909
Article available in :
Volume 4, Issue 2, 2026
Page : 46-49
https://doi.org/10.51271/ICJIM-0075
Article Information
Received : 15 Nis 2026
Accepted : 25 May 2026
Published : 26 May 2026
Corresponding Author :

Büşra Çiftçi: Department of Internal Medicine, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkiye

[email protected]
Citation : Çiftçi B, Yeşil B. The relationship between inflammatory parameters and disease severity in patients with active ulcerative colitis. Intercont J Int Med. 2026;4(2):46-49. doi:10.51271/ICJIM-0075

Read: 86
Download : 53
Cited: 0
_Footer